28 results
425
APGN
Apexigen Inc
8 Jun 22
Business combination disclosure
5:25pm
and brings over 20 years of demonstrated success and leadership in corporate finance.
“We are thrilled to welcome Bill. His deep financial expertise, broad … , recapitalized the company, and was responsible for the strategic planning, development and leadership of the corporate finance function. Mr. Duke also was senior
425
APGN
Apexigen Inc
29 Jun 22
Business combination disclosure
4:39pm
leadership team to support the Company during its next phase of growth as a public company driving long-term value for shareholders.”
Ms. Karson … is a recognized biopharmaceutical executive with a successful track record of strategic leadership, transaction execution, and accelerating value
8-K
EX-99.1
APGN
Apexigen Inc
24 May 23
Pyxis Oncology to Acquire Apexigen
7:02am
with the transaction.
Post-Closing Operations and Leadership
Effective as of the closing of the transaction, the combined company will trade on Nasdaq under … the ticker symbol “PYXS” and the existing Pyxis Oncology leadership team will continue to be responsible for all executive positions, including Lara S
425
APGN
Apexigen Inc
9 May 22
Business combination disclosure
5:07pm
antagonist antibody.
The investor day will feature presentations from Apexigen’s leadership team:
Xiaodong Yang, MD, PhD (CEO, Apexigen)
Frank Hsu, MD
425
APGN
Apexigen Inc
22 Apr 22
Business combination disclosure
4:41pm
Apexigen’s leadership team:
Xiaodong Yang, MD, PhD (CEO, Apexigen)
Frank Hsu, MD (CMO, Apexigen)
Francis Sarena (COO, Apexigen)
A live question
8-K
EX-99.1
lzb1qrnlp659i7jo4w
18 Mar 22
Apexigen and Brookline Capital Acquisition Corp. Joint Conference Call
5:16pm
425
9der50spkau8ar3p15jn
18 Mar 22
Business combination disclosure
5:18pm
425
EX-99.1
1z32p66oa7q4wvln24t0
24 May 23
Business combination disclosure
4:55pm
DEF 14A
k33i otny
28 Mar 22
Definitive proxy
5:30pm
PRE 14A
3i84n8 5zu0eu
18 Mar 22
Preliminary proxy
5:21pm
10-K
r0prxzly542g0k0r
7 Apr 22
Annual report
5:13pm
424B4
58zv1c135gu30s8qf
29 Jan 21
Prospectus supplement with pricing info
10:01am
DRS
4212syd4hwc5m ur
17 Jul 20
Draft registration statement
12:00am
S-1
z4tnraj
14 Aug 20
IPO registration
3:23pm
425
pzw48whud aoe9kmss9
24 May 23
Business combination disclosure
7:05am
S-4
57z13627 chlexngpk
8 Apr 22
Registration of securities issued in business combination transactions
6:37pm
POS AM
q4jnxqat6yxb2jd
4 Apr 23
Prospectus update (post-effective amendment)
4:23pm